SARTORELLO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.509
EU - Europa 181
AS - Asia 117
AF - Africa 1
Totale 1.808
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.507
CN - Cina 62
VN - Vietnam 50
SE - Svezia 37
FI - Finlandia 30
GB - Regno Unito 27
IT - Italia 22
DE - Germania 18
BE - Belgio 14
NL - Olanda 12
UA - Ucraina 11
FR - Francia 3
IE - Irlanda 3
CA - Canada 2
RO - Romania 2
TR - Turchia 2
AT - Austria 1
HU - Ungheria 1
IN - India 1
JP - Giappone 1
PH - Filippine 1
UG - Uganda 1
Totale 1.808
Salva come PNG Salva come JPEG
Città #
Fairfield 307
Chandler 154
Houston 128
Cambridge 115
Woodbridge 114
Ashburn 104
Seattle 102
Ann Arbor 84
Wilmington 76
Jacksonville 56
Dong Ket 50
Princeton 40
San Diego 25
Nanjing 17
Medford 16
Washington 15
Beijing 12
Roxbury 12
Brussels 10
Padova 10
Boardman 8
Helsinki 8
Changsha 7
Des Moines 6
Hebei 6
Shenyang 6
Hefei 5
London 5
Borås 4
Norwalk 4
Waanrode 4
Dublin 3
Kharkiv 3
Redwood City 3
Tianjin 3
Tivoli 3
Florence 2
Indiana 2
Istanbul 2
Milan 2
Budapest 1
Cormeilles-en-Parisis 1
Dallas 1
Dearborn 1
Delhi 1
Guangzhou 1
Kampala 1
Malo 1
Manila 1
Ningbo 1
Rockville 1
Simi Valley 1
Stockholm 1
Taiyuan 1
Tolbert 1
Totale 1.548
Salva come PNG Salva come JPEG
Nome #
A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function. 111
von Willebrand factor propeptide makes it easy to identify the shorter von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. 104
Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. 102
Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. 89
Thromboelastometry profiles in patients undergoing thrombolytic therapy for acute ischaemic stroke 87
Higher and lower active circulating VWF levels: different facets of von Willebrand disease 87
Association between ABO blood group and bleeding phenotype in patients with mild rare bleeding disorders 82
A novel von Willebrand factor mutation (11372S) associated with type 2B-like von Willebrand disease: An elusive phenotype and a difficult diagnosis 80
Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity? 77
Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma 75
Which assay is the most suitable to investigate von Willebrand factor functional activity? 73
Multiple von Willebrand factor mutations in patients with recessive type 1 von Willebrand disease. 71
Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization. 70
Combined partial exon skipping and cryptic splice site activation as a new molecular mechanism for recessive type 1 von Willebrand disease. 69
Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. 69
An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. 66
Endocytosis of exogenous factor V by ex-vivo differentiated megakaryocytes from patients with severe parahaemophilia 64
Microsatellite (GT)(n) repeats and SNPs in the von Willebrand factor gene promoter do not influence circulating von Willebrand factor levels under normal conditions. 63
Combined exon skipping and cryptic splice activation as a new molecular mechanism for recessive type 1 von Willebrand disease. 62
Partial F8 gene duplication (Factor VIII Padua) associated with high factor VIII levels and familial thrombophilia 58
Plasma and platelet von Willebrand factor abnormalities in patients with uremia: lack of correlation with uremic bleeding. 56
Haplotypes of Von Willebrand factor promoter predict thrombotic risk in Cushing's syndrome 52
A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor 52
Identifying carriers of type 2N von Willebrand disease: procedures and significance. 35
Combined hemophilia A and type 2 von Willebrand's disease: defect of both factor VIII level and factor VIII binding capacity of von Willebrand factor. 30
Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study 20
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study 13
Totale 1.817
Salva come PNG Salva come JPEG
Categoria #
all - tutte 4.854
article - articoli 4.745
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.599
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019264 0 0 13 8 7 0 1 29 0 36 90 80
2019/2020407 69 17 5 31 47 28 42 54 48 28 21 17
2020/2021299 13 12 4 32 12 30 13 28 37 17 26 75
2021/2022364 16 29 70 18 6 29 16 43 10 6 53 68
2022/2023302 56 38 7 30 57 31 2 18 38 4 19 2
2023/202465 3 29 33 0 0 0 0 0 0 0 0 0
Totale 1.817